Pituitary Gland Carcinoma

P=N/A, N=200, Recruiting, University Hospital, Basel, Switzerland | Trial completion date: Sep 2025 --> Mar 2026 | Trial primary completion date: Sep 2025 --> Mar 2026

Most patients achieved a mid- to long-term disease-controlled state without additional treatment. Given the potential risk of GH deficiency from further treatment, it may be reasonable to consider patients clinically controlled as long as IGF-1 levels remain normalized, with careful long-term monitoring recommended.

This case underscores the importance of periodically reassessing genetic variants, as reclassification can significantly impact patient management. It also highlights the clinical variability of CNC and the need to screen for CNC features in young patients with acromegaly. Further research is warranted to determine the value ofPRKAR1A testing in isolated GH- and GH/PRL-secreting PA.

Alterations in the protein expression levels of circadian clock genes may contribute to the development and behavior of PAs.

Elevated postoperative plasma GFAP, NfL, and tau might indicate increased risk of long-term postoperative pituitary hormone deficiency. Relative IOH may also contribute to these deficiencies.

Anemia is a frequent and clinically relevant comorbidity in acromegaly, associated with tumor burden, hypopituitarism, treatment intensity. These findings highlight the need for systematic evaluation of anemia in acromegalic patients and underscore the importance of future prospective studies to clarify its complex pathophysiology.

The patient was treated with a somatostatin analog and metformin for glycemic control, followed by carbimazole in preparation for thyroidectomy...Possible mechanisms for regression include perioperative pituitary apoplexy, spontaneous ischemia, or altered vascular dynamics following thyroidectomy. The present case report highlights the importance of reassessing pituitary adenomas following the treatment of coexisting endocrine or compressive disorders and suggests a potential role of vascular factors in pituitary tumor regression.

A high prevalence of osteoporosis and fragility fractures was found in patients with acromegaly, regardless of age, sex, BMI, time from diagnosis, IGF-1 levels, and disease control. More patients with osteoporosis were treated with somatostatin analogs compared to those without osteoporosis. Taken together, our results suggest that the severity of the disease and the need for second-line therapies, may be associated with the increased risk of osteoporosis.

Mechanistically, TLE1 was validated as a direct functional target of miR-184. In summary, our study reveals exosomal miR-184 as a key mediator of CAF-driven PA progression, highlighting its potential as a therapeutic target for PAs.

Despite current pharmacotherapies, patients reported substantial burden due to acromegaly and its treatment, which extends beyond clinical manifestations to impact activities, productivity, and HCRU.

Overall, the lineage-aligned synthesis indicates that NF-PitNETs progress through diverse molecular pathways, with each subtype dominated by distinct regulatory networks. Although many biomarkers show promise, most remain exploratory, highlighting the need for harmonised methods and multicentre validation to support precision diagnostics and prognostic modelling.

These patients also showed heightened sensitivity to several chemotherapeutic and targeted agents, including Cisplatin and Crizotinib. Integrating single-cell sequencing, MR-based causality, clinical validation, and functional experiments, we identified ASPH and PTTG1 as key regulators of LUAD angiogenesis and immune evasion. These findings substantiate ASPH/PTTG1 as promising biomarkers and therapeutic targets, offering new insights into precision therapies integrating anti-angiogenic and immunomodulatory strategies.